Bioventus Q2 revenue dips 2.4%, organic growth 6.2%
Overview
Bioventus Q2 revenue dips 2.4%, organic revenue grows 6.2%
Adjusted EPS rises 31% to $0.21, beating analyst expectations
Co reiterates full-year 2025 guidance for revenue, Adjusted EBITDA, and Non-GAAP EPS
Outlook
Bioventus reiterates 2025 net sales guidance of $560 mln to $570 mln
Company expects 2025 adjusted EBITDA of $112 mln to $116 mln
Bioventus anticipates 2025 non-GAAP EPS of $0.64 to $0.68
Company sees tariff impact as immaterial for 2025 guidance
Result Drivers
DIVESTITURE IMPACT - Revenue decline due to divestiture of Advanced Rehabilitation Business
ORGANIC GROWTH - Organic revenue rose 6.2% driven by double-digit growth in Surgical Solutions and Restorative Therapies
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Beat | $147.70 mln | $145.90 mln (4 Analysts) |
Q2 Adjusted EPS | Beat | $0.21 | $0.2 (3 Analysts) |
Q2 Adjusted EBITDA | $33.80 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Bioventus Inc is $15.00, about 59.1% above its August 5 closing price of $6.14
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 10 three months ago
Press Release: